Outcomes of hypertonic saline inhalation as a treatment modality in nontuberculous mycobacterial pulmonary disease

Eur Respir J. 2019 Jul 11;54(1):1802143. doi: 10.1183/13993003.02143-2018. Print 2019 Jul.

Authors

Anne Huiberts¹, Sanne M H Zweijpfenning¹, Lian J Pennings², Martin J Boeree¹, Jakko van Ingen², Cecile Magis-Escurra¹, Wouter Hoefsloot³

Affiliations

¹ Dept of Pulmonary Diseases, Radboud Center for Infectious diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
² Dept of Medical Microbiology, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
³ Dept of Pulmonary Diseases, Radboud Center for Infectious diseases, Radboud University Medical Center, Nijmegen, The Netherlands wouter.hoefsloot@radboudumc.nl.

PMID: 31000680
DOI: 10.1183/13993003.02143-2018

No abstract available

Publication types

Letter

MeSH terms

Administration, Inhalation
Aged
Female
Humans
Lung Diseases / drug therapy*
Male
Middle Aged
Mycobacterium Infections, Nontuberculous / drug therapy*
Nontuberculous Mycobacteria / drug effects*
Retrospective Studies
Saline Solution, Hypertonic / administration & dosage*
Treatment Outcome

Substances

Saline Solution, Hypertonic